EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Fatal Autoimmune Storm After a Single Cycle of Anti-PD-1 Therapy

Jesús Fuentes-Antrás, Paloma Peinado, Kissy Guevara-Hoyer, Cristina Díaz Del Arco, Silvia Sánchez-Ramón, Carlos Aguado

Hematology/Oncology and Stem Cell Therapy · 2022-01 · 15 (1) · 63-67

DOI: 10.1016/j.hemonc.2020.04.006 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hematology/Oncology and Stem Cell Therapy, 2022-01. Verfasst von Jesús Fuentes-Antrás und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Myasthenia Gravis, Lung Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As immunotherapy agents are incorporated into the routine oncological practice, the number of patients at the risk of immune-related adverse events has increased dramatically. However, the prompt identification and effective management of severe autoimmune complications remain a challenge. We report the case of a patient with metastatic lung adenocarcinoma who experienced a fatal autoimmune storm 3 weeks after the first dose of anti-programmed death receptor-1 (PD-1) agent pembrolizumab, which included thyroiditis, hepatitis, myositis, myocarditis, pneumonitis, and myasthenia gravis. Aggressive autoimmunity was supported by extensive T-cell and macrophage tissue infiltrates and autoantibody positivity. Remarkably, no residual tumor was found at autopsy. This case illustrates the potential harm caused by immunotherapy and our limited knowledge on its prevention, treatment, and association to antitumor efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalAdenocarcinoma of LungMyasthenia GravisLung NeoplasmsHumansImmunotherapyImmunologic Factors

Substanzen

Antineoplastic Agents, ImmunologicalImmunologic Factors

Autor:innen und Institutionen

  • Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain.
  • Department of Clinical Immunology, Hospital Clínico San Carlos, Madrid, Spain.
  • Department of Pathology, Hospital Clínico San Carlos, Madrid, Spain.

Zitieren

APA

Fuentes-Antrás, J., Peinado, P., Guevara-Hoyer, K., Díaz Del Arco, C., Sánchez-Ramón, S., & Aguado, C. (2022). Fatal Autoimmune Storm After a Single Cycle of Anti-PD-1 Therapy. Hematology/Oncology and Stem Cell Therapy, 15(1), 63-67. https://doi.org/10.1016/j.hemonc.2020.04.006

Vancouver

Fuentes-Antrás J, Peinado P, Guevara-Hoyer K, Díaz Del Arco C, Sánchez-Ramón S, Aguado C. Fatal Autoimmune Storm After a Single Cycle of Anti-PD-1 Therapy. Hematology/Oncology and Stem Cell Therapy. 2022;15(1):63-67. doi:10.1016/j.hemonc.2020.04.006

BibTeX
@article{FuentesAntrs2022,
  author = {Fuentes-Antrás, Jesús and Peinado, Paloma and Guevara-Hoyer, Kissy and Díaz Del Arco, Cristina and Sánchez-Ramón, Silvia and Aguado, Carlos},
  title = {Fatal Autoimmune Storm After a Single Cycle of Anti-PD-1 Therapy},
  journal = {Hematology/Oncology and Stem Cell Therapy},
  year = {2022},
  volume = {15},
  number = {1},
  pages = {63--67},
  doi = {10.1016/j.hemonc.2020.04.006}
}
Kostenlos starten →